API

Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.

What are the indications and adverse reactions of Pazopanib?

Pazopanib is indicated for the first-line treatment of advanced renal cell carcinoma or for patients with advanced renal cell carcinoma who have received prior cytokine therapy.

Jul 30,2025  API

Nintedanib:Class, Uses, Synthesis, Mechanism of Action and Toxicity

Nintedanib was initially approved by the U.S. Food and Drug Administration (FDA) in 2014 as a treatment for idiopathic pulmonary fibrosis (IPF).

Jul 30,2025  API

Q:Are erlotinib and gefitinib interchangeable for non-small cell lung cancer treatment?

A:Depends on the circumstances. Gefitinib and erlotinib are both orally active EGFR TKIs but with different structure, which means different affinity with their receptor.

Jul 30,2025  API

Abemaciclib:Drug class, Brand name, Uses and Diet recommendations

Abemaciclib blocks proteins known as CDK (cyclin dependent kinase) 4 and 6. When activity of CDK 4 and 6 is increased, there is a loss of cell cycle control that leads to increased cell growth and div

Jul 30,2025  API

Cinacalcet:Brand name, Uses, Pharmacokinetics and Precautions

Cinacalcet is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium.

Jul 30,2025  API

Sorafenib: An Important Option for the Treatment of Hepatocellular Carcinoma (HCC)

Sorafenib (Nexavar) was approved in the EU and the USA for use in HCC in 2007, and remains the only systemic agent approved for use in this indication.

Jul 30,2025  API

Dasatinib:Class, Uses, Advantages,Usage and Toxicity

Unlike imatinib, another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.

Jul 30,2025  API

BTK inhibitor Ibrutinib:Brand names,Uses,Dietary instructions and Toxicity

Ibrutinib is a small molecule with the ability to form a covalent bond with Cys-481 in the ATP binding domain of BTK. The IC50 of ibrutinib for BTK is 0.5 nM.

Jul 30,2025  API

Nilotinib: Mechanism of Action

Nilotinib shows a important role in the treatment of PVNS and GIST, this article will introduce its mechanism.

Jul 29,2025  API

Uses of Regorafenib in the Treatment of Advanced Cancers

Regorafenib is an effective, orally active TKI with a mechanism of action that enables it to exhibit broad activity in various cancers.

Jul 28,2025  API
Prev12345678910...Next>  Go to Page